Rudolf Lucas

Prof. Rudolf Lucas

Vascular Biology Center, Division of Pulmonary Critical care MedicineMedical College of Georgia at Augusta University, 1460, Laney-Walker Blvd, Augusta, GA 30912, USA
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Open access
HKHrishikesh S. Kulkarni
Hrishikesh S. Kulkarni
JLJanet S. Lee
Janet S. Lee
JBJulie A. Bastarache
Julie A. Bastarache
WKWolfgang Kuebler
Wolfgang Kuebler
GDGregory P. Downey
Gregory P. Downey
GMGutavo Matute-Bello
Gutavo Matute-Bello
Advancements in methods, technology, and our understanding of the pathobiology of lung injury have created the need to update the definition of experimental acute lung injury (ALI). We queried 50 participants with expertise in ALI and acute respiratory distress syndrome using a Delphi method composed of a series of electronic surveys and a virtual workshop. We propose that ALI presents as a “multidimensional entity” characterized by four “domains” that reflect the key pathophysiologic features and underlying biology of human acute respiratory distress syndrome. These domains are 1) histological evidence of tissue injury, 2) alteration of the alveolar–capillary barrier, 3) presence of an inflammatory response, and 4) physiologic dysfunction. For each domain, we present “relevant measurements,” defined as those proposed by at least 30% of respondents. We propose that experimental ALI encompasses a continuum of models ranging from those focusing on gaining specific mechanistic insights to those primarily concerned with preclinical testing of novel therapeutics or interventions. We suggest that mechanistic studies may justifiably focus on a single domain of lung injury, but models must document alterations of at least three of the four domains to qualify as “experimental ALI.” Finally, we propose that a time criterion defining “acute” in ALI remains relevant, but the actual time may vary based on the specific model and the aspect of injury being modeled. The continuum concept of ALI increases the flexibility and applicability of the definition to multiple models while increasing the likelihood of translating preclinical findings to critically ill patients.

1 June 2009 in Biochemical Pharmacology
Verified
Journal Article
Closed access
RLRudolf Lucas
Rudolf Lucas
AVAlexander D. Verin
Alexander D. Verin
SBStephen M. Black
Stephen M. Black
JCJohn D. Catravas
John D. Catravas

18 June 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YCYapeng Cao
Yapeng Cao
XZXiaoyu Zhang
Xiaoyu Zhang
LWLina Wang
Lina Wang
QYQiuhua Yang
Qiuhua Yang
QMQian Ma
Qian Ma
YHYuqing Huo
Yuqing Huo
Increased glycolysis in the lung vasculature has been connected to the development of pulmonary hypertension (PH). We therefore investigated whether glycolytic regulator 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFKFB3)-mediated endothelial glycolysis plays a critical role in the development of PH. Heterozygous global deficiency of Pfkfb3 protected mice from developing hypoxia-induced PH, and administration of the PFKFB3 inhibitor 3PO almost completely prevented PH in rats treated with Sugen 5416/hypoxia, indicating a causative role of PFKFB3 in the development of PH. Immunostaining of lung sections and Western blot with isolated lung endothelial cells showed a dramatic increase in PFKFB3 expression and activity in pulmonary endothelial cells of rodents and humans with PH. We generated mice that were constitutively or inducibly deficient in endothelial Pfkfb3 and found that these mice were incapable of developing PH or showed slowed PH progression. Compared with control mice, endothelial Pfkfb3-knockout mice exhibited less severity of vascular smooth muscle cell proliferation, endothelial inflammation, and leukocyte recruitment in the lungs. In the absence of PFKFB3, lung endothelial cells from rodents and humans with PH produced lower levels of growth factors (such as PDGFB and FGF2) and proinflammatory factors (such as CXCL12 and IL1β). This is mechanistically linked to decreased levels of HIF2A in lung ECs following PFKFB3 knockdown. Taken together, these results suggest that targeting PFKFB3 is a promising strategy for the treatment of PH. Significance Lung endothelial cells express high levels of glucose metabolic enzymes, such as PFKFB3, and consequently produce large amounts of glucose metabolites. These metabolites are able to stabilize the cell signaling molecule HIF2A, similar to that which occurs under hypoxic conditions. This stabilization of HIF2A by glucose metabolites in lung endothelial cells stimulates production of growth and inflammatory factors, thereby enhancing proliferation and inflammation of the pulmonary vessels and exacerbating pulmonary hypertension (PH). In this study, blockade of endothelial PFKFB3 inhibits PH development in rodent models, suggesting that targeting glucose metabolic enzymes is a promising strategy for the treatment of PH.

15 October 2010 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
MBMerouane Bencherif
Merouane Bencherif
PLPatrick M. Lippiello
Patrick M. Lippiello
RLRudolf Lucas
Rudolf Lucas
MMMario B. Marrero
Mario B. Marrero

31 January 2006 in British Journal of Cancer
Verified
Journal Article
Open access
GFG Fürstenberger
G Fürstenberger
RMR von Moos
R von Moos
RLRudolf Lucas
Rudolf Lucas
BTB Thürlimann
B Thürlimann
HSH-J Senn
H-J Senn
EBE-M Boneberg
E-M Boneberg
Circulating endothelial cells (CECs) as well as bone-marrow-derived endothelial precursor cells (EPC) play an important role in neovascularisation and tumour growth. To study the impact of neoadjuvant chemotherapy on the amounts of CEC and their precursor cells, mature CEC and their progenitors were quantified by flow cytometry in peripheral blood of breast cancer patients during anthracycline and/or taxane based neoadjuvant chemotherapy and subsequent surgery in comparison to age-matched healthy controls. Cell numbers were tested for correlation with serum levels of angiopoietin-2, erythropoietin, endostatin, endoglin, VEGF and sVCAM-1 as well as clinical and pathological features of breast cancer disease. Circulating endothelial cells were significantly elevated in breast cancer patients and decreased during chemotherapy, whereas EPC (CD34+/VEGFR-2+) as well as their progenitor cell population CD133+/CD34+ and the population of CD34+ stem cells increased. Concomitantly with the increase of progenitor cells an increase of VEGF, erythropoietin and angiopoietin-2 was observed. These data suggest that chemotherapy can only reduce the amounts of mature CEC, probably reflecting detached cells from tumour vessels, whereas the EPC and their progenitors are mobilised by chemotherapy. Since this mobilisation of EPC may contribute to tumour neovascularisation an early antiangiogenic therapy in combination with chemotherapy could be beneficial for the success of cancer therapy.

11 February 1994 in Science
Verified
Journal Article
Closed access
PDF file
RLRudolf Lucas
Rudolf Lucas
SMStefan Magez
Stefan Magez
RLRobert De Leys
Robert De Leys
LFLucie Fransen
Lucie Fransen
JSJean-Pierre Scheerlinck
Jean-Pierre Scheerlinck
PBPatrick De Baetselier
Patrick De Baetselier
Tumor necrosis factor (TNF), but not lymphotoxin (LT), is directly trypanolytic for salivarian trypanosomes. This activity was not blocked by soluble 55-kilodalton and 75-kilodalton TNF receptors, but was potently inhibited by N,N ′-diacetylchitobiose, an oligosaccharide that binds TNF. Comparative sequence analysis of TNF and LT localized the trypanocidal region, and synthetic peptides were trypanolytic. TNF molecules in which the trypanocidal region was mutated or deleted retained tumoricidal activity. Thus, trypanosome-TNF interactions occur via a TNF domain, probably with lectin-like affinity, which is functionally and spatially distinct from the mammalian TNF receptor binding sites.